Insilico Study of Surfactants Used in Formulation Development as Permeation Glycoprotein Inhibitor Potential

Main Article Content

Eknath D. Ahire
Sanjay J. Kshirsagar


INTRODUCTION: Microbial multidrug resistance (MDR) has become one of the key treatments in many medication regimens throughout the past few decades. The pharmaceutical industry, the animal husbandry industry, and the agriculture industry have all been somewhat impacted as a result of this phenomenon.
MATERIAL AND METHODS: The molecular docking studies with specified ligands were carried out using the Schrodinger Maestro 9.1 software programme. Protein preparation wizard was used to prepare the selected receptors.
RESULTS: The docking simulations revealed the unusual importance of numerous elements in the protein ligand interaction profile, such as hydrogen bonds, lipophilic contacts, metal interactions, pi-pi interaction, and pi-cation interaction. Scoring functions are quick approximation mathematical algorithms used in computational chemistry and molecular modeling to predict the intensity of non-covalent contact between two molecules after they have been docked.
CONCLUSION: The findings of this study may aid in understanding the molecular mechanism of these excipients' possible P-gp inhibitory activity. The current findings will be validated further by formulation development with any P-gp substrate drug molecule, as well as in vitro and in vivo studies for ultimate confirmation.

Article Details

How to Cite
Eknath D. Ahire, & Sanjay J. Kshirsagar. (2023). Insilico Study of Surfactants Used in Formulation Development as Permeation Glycoprotein Inhibitor Potential. Journal of Coastal Life Medicine, 11(2), 644–652. Retrieved from


Monteiro LM, Lione VF, do Carmo FA, do Amaral LH, da Silva JH, Nasciutti LE, Rodrigues CR, Castro HC, de Sousa VP, Cabral LM. Development and characterization of a new oral dapsone nanoemulsion system: permeability and in silico bioavailability studies. International Journal of Nanomedicine. 2012 Sep 28:5175-82.

Alshehri S, Altamimi MA, Hussain A, Imam SS, Singh SK, Faruk A. Morphological transition of M. tuberculosis and modulation of intestinal permeation by food grade cationic nanoemulsion: In vitro-ex vivo-in silico GastroPlus™ studies. Journal of Drug Delivery Science and Technology. 2020 Dec 1;60:101971.

Dahan A, Beig A, Lindley D, Miller JM. The solubility–permeability interplay and oral drug formulation design: Two heads are better than one. Advanced drug delivery reviews. 2016 Jun 1;101:99-107.

Srivalli KM, Lakshmi PK. Overview of P-glycoprotein inhibitors: a rational outlook. Brazilian Journal of Pharmaceutical Sciences. 2012;48:353-67.

Ahire ED, Kshirsagar SJ. Efflux Pump Inhibitors: New Hope in Microbial Multidrug Resistance: Role of Efflux Pump Inhibitors in multidrug resistance protein (P-gp). Community Acquired Infection. 2022 May 10;9.

Zeino M, Saeed ME, Kadioglu O, Efferth T. The ability of molecular docking to unravel the controversy and challenges related to P-glycoprotein—a well-known, yet poorly understood drug transporter. Investigational new drugs. 2014 Aug;32:618-25.

Sethi S, Rana V. In silico–assisted development of supersaturable preconcentrated isotropic mixture of atazanavir for augmenting biopharmaceutical performance in the presence of H2-receptor antagonist. Drug Delivery and Translational Research. 2023 Jan;13(1):339-55.

Mollazadeh S, Sahebkar A, Hadizadeh F, Behravan J, Arabzadeh S. Structural and functional aspects of P-glycoprotein and its inhibitors. Life sciences. 2018 Dec 1;214:118-23.

Akhtar N, Ahad A, Khar RK, Jaggi M, Aqil M, Iqbal Z, Ahmad FJ, Talegaonkar S. The emerging role of P-glycoprotein inhibitors in drug delivery: a patent review. Expert opinion on therapeutic patents. 2011 Apr 1;21(4):561-76.

Ferreira RJ, Ferreira MJ, dos Santos DJ. Molecular docking characterizes substrate-binding sites and efflux modulation mechanisms within P-glycoprotein. Journal of chemical information and modeling. 2013 Jul 22;53(7):1747-60.

Klepsch F, Chiba P, Ecker GF. Exhaustive sampling of docking poses reveals binding hypotheses for propafenone type inhibitors of P-glycoprotein. PLoS computational biology. 2011 May 12;7(5):e1002036.

Kadioglu O, Saeed ME, Valoti M, Frosini M, Sgaragli G, Efferth T. Interactions of human P-glycoprotein transport substrates and inhibitors at the drug binding domain: Functional and molecular docking analyses. Biochemical Pharmacology. 2016 Mar 15;104:42-51.

Schenone M, Dančík V, Wagner BK, Clemons PA. Target identification and mechanism of action in chemical biology and drug discovery. Nature chemical biology. 2013 Apr;9(4):232-40.

Isca VM, Ferreira RJ, Garcia C, Monteiro CM, Dinic J, Holmstedt S, André V, Pesic M, Dos Santos DJ, Candeias NR, Afonso CA. Molecular docking studies of royleanone diterpenoids from Plectranthus spp. as P-glycoprotein inhibitors. ACS Medicinal Chemistry Letters. 2020 Mar 12;11(5):839-45.

Scotti L, JB Mendonca Junior F, M Ishiki H, F Ribeiro F, K Singla R, M Barbosa Filho J, S DaSilva M, T Scotti M. Docking studies for multi-target drugs. Current drug targets. 2017 Apr 1;18(5):592-604.

Leadbeater NE, Marco M. Preparation of polymer-supported ligands and metal complexes for use in catalysis. Chemical Reviews. 2002 Oct 9;102(10):3217-74.

Mukherjee S, Balius TE, Rizzo RC. Docking validation resources: protein family and ligand flexibility experiments. Journal of chemical information and modeling. 2010 Nov 22;50(11):1986-2000.

Morris GM, Lim-Wilby M. Molecular docking. InMolecular modeling of proteins 2008 (pp. 365-382). Humana Press.

Tan W, Mei H, Chao L, Liu T, Pan X, Shu M, Yang L. Combined QSAR and molecule docking studies on predicting P-glycoprotein inhibitors. Journal of computer-aided molecular design. 2013 Dec;27:1067-73.

Surana KR, Ahire ED, Sonawane VN, Talele SG, Talele GS. Molecular Modeling: Novel Techniques in Food and Nutrition Development. InNatural Food Products and Waste Recovery 2021 Jul 8 (pp. 17-31). Apple Academic Press.

Surana KR, Ahire ED, Sonawane VN, Talele SG. Biomolecular and Molecular Docking: A Modern Tool in Drug Discovery and Virtual Screening of Natural Products. InApplied Pharmaceutical Practice and Nutraceuticals 2021 Apr 14 (pp. 209-223). Apple Academic Press.

Ahire ED, Sonawane VN, Surana KR, Talele GS. Drug discovery, drug-likeness screening, and bioavailability: Development of drug-likeness rule for natural products. InApplied pharmaceutical practice and nutraceuticals 2021 Apr 14 (pp. 191-208). Apple Academic Press.

Surana KR, Ahire ED, Sonawane VN, Talele SG, Talele GS. Informatics and methods in nutrition design and development. InNatural Food Products and Waste Recovery 2021 Jul 8 (pp. 33-49). Apple Academic Press.

Palestro PH, Gavernet L, Estiu GL, Bruno Blanch LE. Docking applied to the prediction of the affinity of compounds to P-glycoprotein. BioMed research international. 2014 Oct;2014.

Ranjbar S, Firuzi O, Edraki N, Shahraki O, Saso L, Khoshneviszadeh M, Miri R. Tetrahydroquinolinone derivatives as potent P-glycoprotein inhibitors: design, synthesis, biological evaluation and molecular docking analysis. MedChemComm. 2017;8(10):1919-33.

Mora Lagares L, Minovski N, Caballero Alfonso AY, Benfenati E, Wellens S, Culot M, Gosselet F, Novič M. Homology modeling of the human p-glycoprotein (Abcb1) and insights into ligand binding through molecular docking studies. International journal of molecular sciences. 2020 Jun 5;21(11):4058.

Daddam JR, Dowlathabad MR, Panthangi S, Jasti P. Molecular docking and P-glycoprotein inhibitory activity of flavonoids. Interdisciplinary Sciences: Computational Life Sciences. 2014 Sep;6:167-75.

Mollazadeh S, Sahebkar A, Hadizadeh F, Behravan J, Arabzadeh S. Structural and functional aspects of P-glycoprotein and its inhibitors. Life sciences. 2018 Dec 1;214:118-23.